Literature DB >> 33561483

X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy.

Juan Wang1, Weiguo Xu2, Ning Zhang3, Changsheng Yang4, Hengwei Xu4, Zhongtang Wang4, Baosheng Li5, Jianxun Ding6, Xuesi Chen2.   

Abstract

Concurrent chemoradiotherapy (CCRT) is a standard treatment regimen for medically inoperable stage III non-small-cell lung carcinoma (NSCLC) owing to its superior prognostics compared with the sequential modality. Nevertheless, the current pattern of CCRT still fails to provide satisfactory survival outcome. Furthermore, CCRT is always accompanied by a higher risk of severe side effects, limiting the dose escalation. Herein, an X-ray-responsive polypeptide nanogel (PNG) was developed for on-demand delivery of chemotherapeutic agent triggered by radiotherapy to synergistically improve the efficacy of CCRT with reduced side effects. The smart PNG was formed by crosslinking methoxy poly(ethylene glycol)-block-poly(L-glutamic acid-co-γ-2-chloroethyl-L-glutamate) (mPEG-b-P(LG-co-CELG)) with a diselenide (Se-Se) bond. The doxorubicin (DOX)-loaded polypeptide nanogel (PNG/DOX) exhibited accelerated drug release when exposed to X-ray irradiation as a result of Se-Se bond degradation. With prolonged circulation and enhanced intratumoral accumulation in vivo, PNG/DOX combined with X-ray irradiation exhibited better synergistic antitumor efficacy and fewer side effects toward human A549 lung carcinoma-bearing nude mice. The smart X-ray-responsive nanogel provides a promising bridge between chemotherapy and radiotherapy and enhances the potential application of CCRT in clinic.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Chemoradiotherapy; Diselenide bond; Polypeptide nanogel; X-ray-responsiveness

Year:  2021        PMID: 33561483     DOI: 10.1016/j.jconrel.2021.02.003

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

Review 1.  Recent Advances in Poly(α-L-glutamic acid)-Based Nanomaterials for Drug Delivery.

Authors:  Yu Zhang; Wenliang Song; Yiming Lu; Yixin Xu; Changping Wang; Deng-Guang Yu; Il Kim
Journal:  Biomolecules       Date:  2022-04-25

2.  Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy.

Authors:  Yanhong Liu; Meiyan Wang; Wanru Liu; Jili Jing; Hongshuang Ma
Journal:  Front Bioeng Biotechnol       Date:  2022-05-02

3.  Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin.

Authors:  Yang-Feng Lv; Zhi-Qiang Deng; Qiu-Chen Bi; Jian-Jun Tang; Hong Chen; Chuan-Sheng Xie; Qing-Rong Liang; Yu-Hua Xu; Rong-Guang Luo; Qun Tang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  Dissolving microneedles delivering cancer cell membrane coated nanoparticles for cancer immunotherapy.

Authors:  Wonchan Park; Keum Yong Seong; Hye Hyeon Han; Seung Yun Yang; Sei Kwang Hahn
Journal:  RSC Adv       Date:  2021-03-11       Impact factor: 3.361

Review 5.  Advances in Nanofabrication Technology for Nutraceuticals: New Insights and Future Trends.

Authors:  Rachitha Puttasiddaiah; Rohitha Lakshminarayana; Nandini Lalithadripura Somashekar; Vijai Kumar Gupta; Baskaran Stephen Inbaraj; Zeba Usmani; Vinay Basavegowda Raghavendra; Kandi Sridhar; Minaxi Sharma
Journal:  Bioengineering (Basel)       Date:  2022-09-16

6.  Synergic fabrication of pembrolizumab loaded doxorubicin incorporating microbubbles delivery for ultrasound contrast agents mediated anti-proliferation and apoptosis.

Authors:  Huilin Liu; Xing Li; Zihe Chen; Lianjie Bai; Ying Wang; Weiyang Lv
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.